Orchestra BioMed Holdings, Inc. OBIO
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 91.00K | 88.00K | 110.00K | 30.92M | 861.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 91.00K | 88.00K | 110.00K | 30.92M | 861.00K |
| Cost of Revenue | 28.00K | 25.00K | 32.00K | 51.00K | 49.00K |
| Gross Profit | 63.00K | 63.00K | 78.00K | 30.87M | 812.00K |
| SG&A Expenses | 5.63M | 5.83M | 6.37M | 7.29M | 7.10M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.39M | 22.44M | 22.19M | 24.16M | 21.17M |
| Operating Income | -23.30M | -22.36M | -22.08M | 6.75M | -20.31M |
| Income Before Tax | -18.75M | -23.76M | -20.69M | 6.25M | -20.83M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -18.75M | -23.76M | -20.69M | 6.25M | -20.83M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.75M | -23.76M | -20.69M | 6.25M | -20.83M |
| EBIT | -23.30M | -22.36M | -22.08M | 6.75M | -20.31M |
| EBITDA | -23.20M | -22.26M | -21.99M | 6.84M | -20.23M |
| EPS Basic | -0.30 | -0.38 | -0.33 | 0.10 | -0.40 |
| Normalized Basic EPS | -0.24 | -0.23 | -0.23 | 0.06 | -0.25 |
| EPS Diluted | -0.30 | -0.38 | -0.33 | 0.10 | -0.40 |
| Normalized Diluted EPS | -0.24 | -0.23 | -0.23 | 0.06 | -0.25 |
| Average Basic Shares Outstanding | 64.62M | 63.81M | 62.72M | 61.97M | 52.19M |
| Average Diluted Shares Outstanding | 64.62M | 63.81M | 62.72M | 61.97M | 52.19M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |